lurtotecan has been researched along with Thrombopenia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Creemers, GJ; de Boer-Dennert, M; DePee, S; Gerrits, CJ; Harteveld, M; Planting, AS; Pritchard, JF; Schellens, JH; Verweij, J; Wissel, P | 1 |
| Baker, SD; Burke, TG; Burris, HA; DePee, S; Eckardt, JR; Eckhardt, SG; Fields, S; Kuhn, JG; Kunka, R; Littlefield, D; Rodriguez, G; Rothenberg, ML; Rowinsky, EK; Smith, L; Thurman, A; Von Hoff, DD; Warner, DL; White, L; Wissel, P | 1 |
| Bos, AM; Cameron, T; de Jonge, MJ; de Vries, EG; Groen, HJ; Hamilton, M; Kehrer, DF; Loos, WJ; Sparreboom, A; Verweij, J | 1 |
3 trial(s) available for lurtotecan and Thrombopenia
| Article | Year |
|---|---|
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Fatigue; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Stomatitis; Thrombocytopenia; Topoisomerase I Inhibitors; Treatment Outcome; Vomiting | 1997 |
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1998 |
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Thrombocytopenia | 2002 |